Alyeska Investment Group, L.P. Sage Therapeutics, Inc. Transaction History

Alyeska Investment Group, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $23.3 Million - $29.5 Million	-153,254 Reduced 98.47%	2,375 $383,000
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $2.72 Million - $7.5 Million	44,832 Added 40.46%	155,629 $25.6 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $6.8 Million - $9.81 Million	110,797	110,797 $6.9 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.